ES2039773T3 - Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. - Google Patents

Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.

Info

Publication number
ES2039773T3
ES2039773T3 ES89114617T ES89114617T ES2039773T3 ES 2039773 T3 ES2039773 T3 ES 2039773T3 ES 89114617 T ES89114617 T ES 89114617T ES 89114617 T ES89114617 T ES 89114617T ES 2039773 T3 ES2039773 T3 ES 2039773T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
treatment
preparing
procedure
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89114617T
Other languages
English (en)
Spanish (es)
Inventor
Michael Dr Dorschug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2039773T3 publication Critical patent/ES2039773T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES89114617T 1988-08-13 1989-08-08 Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. Expired - Lifetime ES2039773T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827533A DE3827533A1 (de) 1988-08-13 1988-08-13 Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2039773T3 true ES2039773T3 (es) 1996-07-16

Family

ID=6360797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89114617T Expired - Lifetime ES2039773T3 (es) 1988-08-13 1989-08-08 Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.

Country Status (18)

Country Link
US (1) US5177058A (https=)
EP (1) EP0357978B1 (https=)
JP (1) JPH02101022A (https=)
KR (1) KR900002801A (https=)
AT (1) ATE75945T1 (https=)
AU (1) AU621648B2 (https=)
CA (1) CA1332354C (https=)
DE (2) DE3827533A1 (https=)
DK (1) DK395689A (https=)
ES (1) ES2039773T3 (https=)
FI (1) FI95202C (https=)
GR (1) GR3005326T3 (https=)
HU (1) HU203670B (https=)
IE (1) IE61266B1 (https=)
NO (1) NO178914C (https=)
NZ (1) NZ230280A (https=)
PT (1) PT91420B (https=)
ZA (1) ZA896149B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE4024434A1 (de) * 1990-08-01 1992-02-13 Fresenius Ag Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CZ2004710A3 (cs) * 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
EP1620465A2 (en) * 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143591A (en) * 1936-09-26 1939-01-10 Univ Alberta Therapeutic preparation and process of making and using it
US2354211A (en) * 1940-07-02 1944-07-25 Burroughs Wellcome Co Insulin preparation
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides

Also Published As

Publication number Publication date
NO893239L (no) 1990-02-14
US5177058A (en) 1993-01-05
AU621648B2 (en) 1992-03-19
DK395689D0 (da) 1989-08-11
EP0357978B1 (de) 1992-05-13
FI95202B (fi) 1995-09-29
FI893783L (fi) 1990-02-14
NO178914C (no) 1996-07-03
CA1332354C (en) 1994-10-11
PT91420B (pt) 1995-05-04
NO178914B (no) 1996-03-25
ZA896149B (en) 1990-04-25
NZ230280A (en) 1991-09-25
FI893783A0 (fi) 1989-08-10
HUT50443A (en) 1990-02-28
ATE75945T1 (de) 1992-05-15
IE61266B1 (en) 1994-10-19
DE3827533A1 (de) 1990-02-15
KR900002801A (ko) 1990-03-23
HU203670B (en) 1991-09-30
FI95202C (fi) 1996-01-10
IE892594L (en) 1990-02-13
JPH02101022A (ja) 1990-04-12
DE58901401D1 (de) 1992-06-17
NO893239D0 (no) 1989-08-11
EP0357978A1 (de) 1990-03-14
DK395689A (da) 1990-02-14
AU3951489A (en) 1990-02-15
PT91420A (pt) 1990-03-08
GR3005326T3 (https=) 1993-05-24

Similar Documents

Publication Publication Date Title
ES2039773T3 (es) Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
IT1236688B (it) Procedimento e dispositivo per la creazione di una miscela combustibile-aria comburente da addurre a una combustione.
ES2195220T3 (es) Acidos sulfonilaminocarboxilicos.
DE3679908D1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
FI95539C (fi) Transdermaalinen järjestelmä, sen valmistusmenetelmä ja käyttö
ES2165640T3 (es) Acidos diaminocarboxilicos sustituidos.
ATE71291T1 (de) Pharmazeutische zubereitung mit verzoegerter freigabe.
AR004486A1 (es) Uso de tripicolinato cromico en la preparacion de un medicamento
DE3887338D1 (de) Superaktive menschliche insulin-analoge.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
SE8204873L (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
ATE116849T1 (de) Pharmazeutische verwendung von fettsäuren.
ES2077674T3 (es) Aumento de la produccion de proteinas en animales.
DK0413343T3 (da) Furanderivater
KR940005283A (ko) 활성 성분으로 글리센틴을 함유하는 약제
ATE124627T1 (de) Diclofenac-natrium enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
EA200000039A1 (ru) Лечение диабета тиазолидиндионом и сульфонилмочевиной
DE3880561D1 (de) Actinoninderivate mit physiologischen aktivitaeten.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE3877365D1 (de) Arzneimittel mit methylcellulose.
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 357978

Country of ref document: ES

FG2A Definitive protection

Ref document number: 0357978

Country of ref document: ES